Výsledky vyhledávání - "EM Barreiro-Fernandez"

1ISG-021 Indirect comparison of brigatinib versus alectinib in ALK positive non-small cell lung cancer

Autor: FJ Salmeron Navas, M Dominguez Cantero, EJ Alegre-Del Rey, Silvia Fénix-Caballero, EM Barreiro-Fernandez, C Moreno-Ramos

Publikováno v: Section 1: Introductory statements and governance.

Background and importance ALK gene mutation occurs in 3–5% of patients with non-small cell lung cancer (NSCLC). Brigatinib and alectinib are potent ALK tyrosine kinase inhibitors, indicated in NSCLC. Aim and objectives The aim of this study was to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::017174bafb51a17a40e8399c644d7cc4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.2

Zobrazit plný text záznamu

4CPS-296 Impact of the COVID-19 pandemic on clinical lung cancer management

Autor: C Martínez Díaz, EM Barreiro Fernandez, EJ Alegre-Del Rey, FJ Salmeron Navas, M Dominguez Cantero, S. Fénix Caballero

Publikováno v: Section 4: Clinical pharmacy services.

Background and importance The SARS-CoV-2 pandemic could have changed the clinical management of cancer patients because of travel restrictions, overloading of hospital systems and disruption of treatment. Lung cancer patients constitute a vulnerable

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0090f1368b02ccbf0f2c2319dd0d6ac4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.128

Zobrazit plný text záznamu

2SPD-004 Efficiency of precision dosing with intravenous immunoglobulins in patients with haematological malignancies

Autor: C Moreno-Ramos, MP Briceño-Casado, FJ Salmeron-Navas, M Dominguez Cantero, EM Barreiro-Fernandez

Publikováno v: Section 2: Selection, Procurement and Distribution.

Background and importance Intravenous immunoglobulin (IVIG) therapy is relatively expensive and requires careful use. IVIG dosing is based on actual body weight (ABW) but it is mainly distributed in the extracellular and intravascular space and minim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3473c1e260a778ebe71159899e1503e8
https://doi.org/10.1136/ejhpharm-2020-eahpconf.23

Zobrazit plný text záznamu

4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors

Autor: M Dominguez Cantero, EM Barreiro-Fernandez, Silvia Fénix-Caballero, FJ Salmeron Navas, C Martinez-Diaz

Publikováno v: Section 4: Clinical Pharmacy Services.

Background and importance The therapeutic option in patients with metastatic non-small cell lung cancer (mNSCLC) after chemotherapy is based on the immune checkpoint inhibitors (ICI). Aim and objectives The aim of this study was to analyse the effect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67d90b621601d359cee59de50035a064
https://doi.org/10.1136/ejhpharm-2020-eahpconf.198

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání